Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Macro Lett ; 13(3): 288-295, 2024 Mar 19.
Article in English | MEDLINE | ID: mdl-38368530

ABSTRACT

We report a facile stimuli-responsive strategy to generate reactive oxygen and nitrogen species (ROS and RNS) in the biological milieu from a photocleavable water-soluble block copolymer under visible light irradiation (427 nm, 2.25 mW/cm2). An anthraquinone-based water-soluble polymeric nitric oxide (NO) donor (BCPx-NO) is synthesized, which exhibits NO release in the range of 40-65 µM within 10 h of photoirradiation with a half-life of 30-103 min. Additionally, BCPx-NO produces peroxynitrite (ONOO-) and singlet oxygen (1O2) under photoirradiation. To understand the mechanism of NO release and photolysis of the functional group under blue light, we prepared a small-molecule anthraquinone-based N-nitrosamine (NOD). The cellular investigation of the effect of spatiotemporally controlled ONOO- and 1O2 generation from the NO donor polymeric nanoparticles in a triple negative breast adenocarcinoma (MDA-MB-231) under visible light irradiation (white light, 5.83 mW/cm2; total dose 31.5 J/cm2) showed an IC50 of 0.6 mg/mL. The stimuli-responsive strategy using a photolabile water-soluble block copolymer employed to generate ROS and RNS in a biological setting widens the horizon for their potential in cancer therapy.


Subject(s)
Neoplasms , Peroxynitrous Acid , Humans , Peroxynitrous Acid/therapeutic use , Reactive Oxygen Species/therapeutic use , Polymers/therapeutic use , Reactive Nitrogen Species/therapeutic use , Light , Oxygen/therapeutic use , Nitric Oxide/therapeutic use , Anthraquinones/therapeutic use , Neoplasms/drug therapy
2.
Mil Med Res ; 10(1): 31, 2023 Jul 14.
Article in English | MEDLINE | ID: mdl-37443101

ABSTRACT

Rheumatoid arthritis (RA) is a systemic autoimmune disease that is primarily manifested as synovitis and polyarticular opacity and typically leads to serious joint damage and irreversible disability, thus adversely affecting locomotion ability and life quality. Consequently, good prognosis heavily relies on the early diagnosis and effective therapeutic monitoring of RA. Activatable fluorescent probes play vital roles in the detection and imaging of biomarkers for disease diagnosis and in vivo imaging. Herein, we review the fluorescent probes developed for the detection and imaging of RA biomarkers, namely reactive oxygen/nitrogen species (hypochlorous acid, peroxynitrite, hydroxyl radical, nitroxyl), pH, and cysteine, and address the related challenges and prospects to inspire the design of novel fluorescent probes and the improvement of their performance in RA studies.


Subject(s)
Arthritis, Rheumatoid , Synovitis , Humans , Fluorescent Dyes/therapeutic use , Arthritis, Rheumatoid/diagnostic imaging , Arthritis, Rheumatoid/drug therapy , Synovitis/diagnosis , Biomarkers , Reactive Nitrogen Species/therapeutic use , Reactive Oxygen Species
3.
FEMS Microbiol Rev ; 37(6): 955-89, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23802986

ABSTRACT

Reactive oxygen species (ROS) can attack a diverse range of targets to exert antimicrobial activity, which accounts for their versatility in mediating host defense against a broad range of pathogens. Most ROS are formed by the partial reduction in molecular oxygen. Four major ROS are recognized comprising superoxide (O2•-), hydrogen peroxide (H2O2), hydroxyl radical (•OH), and singlet oxygen ((1)O2), but they display very different kinetics and levels of activity. The effects of O2•- and H2O2 are less acute than those of •OH and (1)O2, because the former are much less reactive and can be detoxified by endogenous antioxidants (both enzymatic and nonenzymatic) that are induced by oxidative stress. In contrast, no enzyme can detoxify •OH or (1)O2, making them extremely toxic and acutely lethal. The present review will highlight the various methods of ROS formation and their mechanism of action. Antioxidant defenses against ROS in microbial cells and the use of ROS by antimicrobial host defense systems are covered. Antimicrobial approaches primarily utilizing ROS comprise both bactericidal antibiotics and nonpharmacological methods such as photodynamic therapy, titanium dioxide photocatalysis, cold plasma, and medicinal honey. A brief final section covers reactive nitrogen species and related therapeutics, such as acidified nitrite and nitric oxide-releasing nanoparticles.


Subject(s)
Anti-Bacterial Agents , Bacteria , Honey , Infections/therapy , Neoplasms/therapy , Reactive Oxygen Species , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Antioxidants/metabolism , Antioxidants/pharmacology , Bacteria/drug effects , Bacteria/metabolism , Catalysis , Honey/analysis , Humans , Hyperbaric Oxygenation , Oxidative Stress , Photochemotherapy , Plasma Gases , Reactive Nitrogen Species/metabolism , Reactive Nitrogen Species/therapeutic use , Reactive Oxygen Species/chemistry , Reactive Oxygen Species/metabolism , Reactive Oxygen Species/therapeutic use
4.
Br J Pharmacol ; 141(1): 172-82, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14662723

ABSTRACT

1. The contribution of nitric oxide (NO) and peroxynitrite (PN) to inflammation in a zymosan-induced (1 mg, intra-articular, i.art.) rat model of arthritis was assessed by histopathology and by measuring the glycosaminoglycan (GAG) content of the articular cartilage. 2. Progression of the chronic synovitis in zymosan-induced arthritis (ZYA) was associated with increased nitrite and nitrotyrosine (3-NT) levels in the joint exudates that paralleled a progressive loss of the GAG content. An increase in 3-NT was also observed after i.art. PN. 3. The nonselective nitric oxide synthase (NOS) inhibitor l-N(G)-nitroarginine methyl ester (25-75 mg x kg(-1)day(-1)) or the selective inducible NOS inhibitor aminoguanidine (50-100 mg x kg(-1)day(-1)) given 1 h before (prophylactic) or 3 days after (therapeutic) injection of the zymosan ameliorated the synovitis, but worsened the GAG loss, as measured at the end of the experiment (day 7). 4. The PN scavenger uric acid (100-250 mg x kg(-1) i.p. four times daily) given prophylactically until the end of the experiment (day 14), in a dose compatible with its PN scavenging activity, significantly decreased both the synovitis and the GAG loss. 5. In conclusion, PN formation is associated with cartilage damage in addition to proinflammatory activity in ZYA. NOS inhibitors and a PN scavenger were able to reduce the cellular infiltration, while displaying opposite effects on cartilage homeostasis either by enhancing or ameliorating the damage, respectively.


Subject(s)
Arthritis, Experimental/chemically induced , Cartilage, Articular/drug effects , Free Radical Scavengers/therapeutic use , Nitric Oxide/adverse effects , Reactive Nitrogen Species/antagonists & inhibitors , Tyrosine/analogs & derivatives , Zymosan/adverse effects , Animals , Cartilage, Articular/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Free Radical Scavengers/pharmacology , Glycosaminoglycans/antagonists & inhibitors , Glycosaminoglycans/chemistry , Glycosaminoglycans/metabolism , Guanidines/pharmacology , Guanidines/therapeutic use , Injections, Intra-Articular , Injections, Intraperitoneal , Male , NG-Nitroarginine Methyl Ester/administration & dosage , NG-Nitroarginine Methyl Ester/pharmacology , NG-Nitroarginine Methyl Ester/therapeutic use , Nitric Oxide/antagonists & inhibitors , Nitric Oxide/chemistry , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/pharmacology , Nitric Oxide Synthase/therapeutic use , Nitrites/antagonists & inhibitors , Nitrites/chemistry , Peroxynitrous Acid/administration & dosage , Peroxynitrous Acid/pharmacology , Rats , Rats, Wistar , Reactive Nitrogen Species/therapeutic use , Synovial Fluid/chemistry , Synovial Fluid/drug effects , Synovial Fluid/metabolism , Synovial Membrane/drug effects , Synovial Membrane/physiopathology , Synovial Membrane/ultrastructure , Synovitis/chemically induced , Synovitis/drug therapy , Tyrosine/antagonists & inhibitors , Tyrosine/biosynthesis , Tyrosine/chemistry , Uric Acid/administration & dosage , Uric Acid/blood , Uric Acid/pharmacology , Zymosan/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...